<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272817</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#13-6255</org_study_id>
    <nct_id>NCT01272817</nct_id>
  </id_info>
  <brief_title>Nonmyeloablative Allogeneic Transplant</brief_title>
  <acronym>Mini-allo</acronym>
  <official_title>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses
      including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative
      syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment</measure>
    <time_frame>One year</time_frame>
    <description>Evaluation of engraftment of donor stem cells by bone marrow examinations at days 30, 100, and 360 after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease</measure>
    <time_frame>One year</time_frame>
    <description>Assess the incidence and severity of acute and/or chronic GVHD for patients transplanted on this protocol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aplastic Anemia</condition>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Breast Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Thymoma</condition>
  <arm_group>
    <arm_group_label>Cladribine + melphalan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cladribine + melphalan conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Total lymphoid irradiation conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Transplant</intervention_name>
    <description>Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day</description>
    <arm_group_label>Cladribine + melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Transplant</intervention_name>
    <description>Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)</description>
    <arm_group_label>TLI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 55 years or

          2. Age &lt; 55 and LVEF &lt; 45% or creatinine clearance &lt; 60 ml/min

          3. Ability to cover the cost of the transplant, necessary medications, and
             transportation/housing.

          4. Caregiver must be available while outpatient

        Guidelines for Cladribine-Melphalan-based conditioning:

          -  Bone Marrow Failure States Severe Aplastic Anemia (relapsed following
             immunosuppressive therapy) Paroxysmal Nocturnal Hemoglobinuria (poor prognostic
             features or hemosiderosis)

          -  AML (first CR except for t(15;17), inv16, t(8,21); second CR; relapse failing second
             induction attempt)

          -  ALL (first CR with at least one poor prognostic feature; second or greater CR; relapse
             failing reinduction attempt)

          -  MDS (RAEB, RAEBiT, CMMoL)

          -  CML (chronic phase; accelerated phase; blast phase following reinduction attempt; 2nd
             chronic or accelerated phase following gleevec therapy

          -  Hodgkin's lymphoma (first or greater relapse)

          -  Non-Hodgkin's Lymphoma

          -  Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR
             Sensitive or refractory relapse

          -  Indolent Histology Second or greater relapse

          -  Mantle Cell Lymphoma (any Stage - must have received induction chemotherapy)

          -  Multiple Myeloma (10% residual plasmacytosis following anthracycline-based
             chemotherapy or residual disease following autologous transplant)

          -  Waldenstrom Macroglobulinemia (must have failed either purine analogue-based
             chemotherapy (Fludara or 2CdA) or standard CVP therapy; hyperviscosity or cytopenias)

        Guidelines for total lymphoid irradiation-based conditioning

          -  MDS (RA, RARS)

          -  CLL (Rai stage III or IV - must have received at least two different treatment
             regimens in the past)

          -  Breast Cancer (symptomatic metastatic disease, who have failed standard chemotherapy)

          -  Renal Cell Cancer (metastatic disease at multiple sites)

          -  Malignant Melanoma (metastatic disease at multiple sites)

          -  Sarcoma (all subtypes presently, unresectable metastatic disease)

          -  Ovarian Cancer (stage III or IV, platinum insensitive disease, i.e. progression within
             6 months of initial platinum chemotherapy)

          -  Thymoma (unresectable disease)

        Exclusion Criteria:

          1. Prior allogeneic stem cell or bone marrow transplant

          2. Current or past history of invasive mycotic infection

          3. Breast Feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey W. Andrey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Burian</last_name>
    <phone>858-554-2845</phone>
    <email>burian.carol@scrippshealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Nelson, R.N.</last_name>
      <phone>858-554-2814</phone>
      <email>nelson.cynthia@scrippshealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Cobarrubia, R.N.</last_name>
      <phone>858-554-2853</phone>
      <email>cobarrubia.laurie@scrippshealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey W. Andrey, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James R. Mason, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William E. Miller, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Health</investigator_affiliation>
    <investigator_full_name>Jeffrey Andrey, MD</investigator_full_name>
    <investigator_title>Director, Unrelated Donor Transplantation</investigator_title>
  </responsible_party>
  <keyword>Nonmyeloablative transplant</keyword>
  <keyword>Allogeneic transplant</keyword>
  <keyword>Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

